IL1B and COVID-19: Positively, hospitalized COVID-19 patients with oral administration of nano-curcumin formulation can modulate the inflammatory cytokine expression and secretion, such as IFN-γ, IL-1β, IL-6, and TNF-α (Kishimoto et al., 2021; Asadirad et al., 2022); regulate inflammatory immune responses to accelerate the recovery of the acute inflammatory phase; and shorten total recovery time (Ahmadi et al., 2021; Saber-Moghaddam et al., 2021).